Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification.
Journal: medRxiv : the preprint server for health sciences
Published: April 20, 2026
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.
Journal: JCO precision oncology
Published: September 02, 2025
Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer.
Journal: Cancer cell
Published: April 14, 2025
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 24, 2025
Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.
Journal: JCO precision oncology
Published: December 06, 2024
Transcriptionally Active Human Papillomavirus Infection in a Minority of Esophageal Squamous Cell Carcinomas in North America.
Journal: The American journal of surgical pathology
Published: May 10, 2024
Author Correction: Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting.
Journal: NPJ precision oncology
Published: May 06, 2024
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.
Journal: Cancer immunology research
Published: February 07, 2024
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.
Journal: Journal for immunotherapy of cancer
Published: January 09, 2024
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer.
Journal: Cancer immunology research
Published: December 12, 2023
Last Updated: 09/26/2026